Trial Profile

A randomized, placebo-controlled Phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CVT-130 in healthy volunteers, along with cardiac and mitochondrial biomarkers.

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 13 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Nov 2025 New trial record
14 Oct 2025 According to Corventum media release, this study is designed to identify an optimal dose for a subsequent Phase 2 trial in cancer patients. Corventum worked closely with the FDA to align on the Phase 1 study design, which reflects the intended dosing strategy for the Phase 2 clinical trial.
14 Oct 2025 According to Corventum media release, company announced the clearance by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for CVT-130 for the prevention of anthracycline-related cardiotoxicity. The company plans to initiate a first-in-human Phase 1 clinical trial in the second quarter of 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com